Open AccessNew Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
Author(s) -
Phillipp Hartmann,
Bernd Schnabl
Publication year - 2021
Publication title -
seminars in liver disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.874
H-Index - 126
eISSN - 1098-8971
pISSN - 0272-8087
DOI - 10.1055/s-0040-1719174
Subject(s) - synbiotics , nonalcoholic fatty liver disease , microbiome , medicine , fecal bacteriotherapy , intestinal microbiome , inflammatory bowel disease , gastroenterology , liver disease , disease , dysbiosis , liver transplantation , fatty liver , randomized controlled trial , antibiotics , transplantation , bioinformatics , probiotic , biology , microbiology and biotechnology , bacteria , genetics , clostridium difficile
Alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are important causes of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of both ALD and NAFLD. Here we describe associated changes in the intestinal microbiota, and we detail randomized clinical trials in ALD and NAFLD which evaluate treatments modulating the intestinal microbiome including fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and antibiotics. Finally, we discuss precision medicine approaches targeting the intestinal microbiome to ameliorate ALD and NAFLD.